GLAUKOS Corp 4

Director Leana Wen received a routine grant of 2,987 Glaukos Corp stock options at a corrected exercise price of $106.52 per share, vesting in one year.

On May 28, 2026, Director Leana Wen received a grant of 2,987 stock options of Glaukos Corp with an exercise price of $106.52 per share under the issuer’s Director Compensation Policy, vesting in full on the one-year anniversary of the grant date; this Form 4/A solely amends the previously reported incorrect exercise price of $53.57 to the correct $106.52 and does not change the number of options granted. Based on the reported 2,987 options and the stated exercise price, the notional face value of the grant is approximately $318,500, while the in-the-money value using the current share price of $134.65 is about $84,000. Following this grant, Dr. Wen beneficially owns 2,987 derivative securities (stock options) representing the right to acquire an equal number of common shares upon exercise, and the estimated current market value of the underlying common stock is about $402,000, though actual value realizable will depend on future share prices and vesting. As this is a routine director compensation award in option form rather than an open-market purchase or sale, it primarily reflects standard board compensation rather than an active bullish or bearish trading signal.

Filing Facts

CIK

1192448

Ticker

GKOS

Form

4

Source Type

fda

Accession

0001847598-26-000008

Alert Tier

5